Affinnova, Inc.

The Boston Globe features Affinnova, "The perfect supermarket cereal aisle?"

The Boston Globe features Affinnova, "The perfect supermarket cereal aisle?"

July 15, 2011

At first glance, there would seem to be little overlap between algorithms developed for genetic research and the ways consumers shop for breakfast cereal, but Affinnova Inc., a Waltham company founded by two Massachusetts Institute of Technology PhDs, is making that connection.

In a recent press release, the market research technology firm disclosed that it was working on a project for Post Foods, which is known for such cereals as Grape-Nuts and Shredded Wheat, among many others.

Agios Pharmaceuticals, Inc.

Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer

Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer

July 14, 2011

Further Validates the Power of Agios’s Cancer Metabolism Research Capabilities

Pronutria Biosciences

Cambridge startup has tech to grow nutrients without farmland

Cambridge startup has tech to grow nutrients without farmland

July 13, 2011

One of the latest companies to come out of Flagship VentureLabs, Essentient Inc. of Cambridge, Mass., is working on an approach to producing nutrients for human consumption that doesn’t require arable land, Essentient CEO David Berry said in an interview.

LS9

LS9 Planning Brazil’s Biggest Plant to Make Biofuels, Chemicals

LS9 Planning Brazil’s Biggest Plant to Make Biofuels, Chemicals

July 8, 2011

LS9 Inc., a closely held U.S. biotechnology company, may build Brazil’s biggest biofuel and specialty chemicals factory as more companies seek to produce new products from sugar cane, the world’s cheapest fuel crop.

The company is planning a facility may be able to produce as much as 200 million gallons (758 million liters) of fuel and chemicals a year, more than two-thirds bigger than Brazil’s largest biofuels plant, South San Francisco, California-based LS9’s Chief Executive Officer Edward Dineen said in an interview.

LS9

LS9 Announces Collaboration with MAN Latin America To Test LS9's UltraClean Diesel in Brazilian Fleet

LS9 Announces Collaboration with MAN Latin America To Test LS9's UltraClean Diesel in Brazilian Fleet

July 7, 2011

SAO PAULO, BRAZIL and SOUTH SAN FRANCISCO, CA - July 7, 2011 - LS9, Inc., a technology leader in the development of sustainable products, announced that it has begun a collaboration with MAN Latin America, a leading Brazilian engineering and vehicles manufacturing company, to test LS9's renewable diesel in both stationary engines and operational fleet vehicles in Brazil.

LS9

LS9 Extends Research In Synthetic Hydrocarbon Products with Chevron

LS9 Extends Research In Synthetic Hydrocarbon Products with Chevron

July 11, 2011

SOUTH SAN FRANCISCO, CA - July 11, 2011 - LS9 Inc., a technology leader in the development of sustainable products, today announced it will carry out a second phase of research with Chevron Technology Ventures, a division of Chevron U.S.A, Inc. This program is directed at further improving LS9's platform technology to produce specific pure hydrocarbon products. This second phase follows Chevron's initial testing and evaluation of LS9's technology solution.

RISING STAR: Flagship's Berry Harkens Back To Venture Capital's Roots

RISING STAR: Flagship's Berry Harkens Back To Venture Capital's Roots

July 1, 2011

From the July issue of Private Equity Analyst

While studying at Massachusetts Institute of Technology and Harvard Medical School, Flagship Ventures Partner David Berry knew he had several career options. Although he wasn't sure which path to take, he was fairly certain about what he didn't want.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

June 20, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform™ (deuterated chemical entity platform). CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

Concert Pharmaceuticals, Inc.

Concert Announces Milestone Achievement in GlaxoSmithKline Collaboration

Concert Announces Milestone Achievement in GlaxoSmithKline Collaboration

June 20, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline (GSK) for its HIV protease inhibitor (HIV-PI) development program, resulting in a $4 million milestone payment to Concert. The strategic alliance with GSK was formed in 2009. In the HIV development program a number of deuterium modified-versions of atazanavir were evaluated preclinically, and a subset was selected for further testing in early human clinical studies.

Selecta Biosciences, Inc.

The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes

The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes

June 9, 2011

New York, NY, and Watertown, MA – June 9, 2011 – The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.